Celgene (CELG-$60.11) chief executive Sol Barer predicts Revlimid will win regulatory approval as front-line treatment for newly diagnosed multiple myeloma (MM) patients in both U.S. and European markets. However, to win broader labeling and expand its European footprint, Celgene’s best-selling product will need to show a six to eight month difference in progression-free survival to be considered significant, said oncologists surveyed by Pharmawire.
Wall Street analysts are falling all over each other to trumpet the growth prospects for the drug with approved maintenance dose settings. But what happens to Celgene if final results of the MM-015 trial fail to reveal significant differences between induction with its flagship drug Revlimid and without it? Continue Reading….
Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.